Antigen-binding polypeptides and their uses
First Claim
Patent Images
1. A method of making a bispecific antigen-binding polypeptide (ABP) comprising a sequence selected from SEQ ID NO:
- 19, 21, 23, 24, 26, 28, 30, 31, and comprising a ribosomally incorporated non-naturally encoded amino acid substitution, wherein the bispecific ABP is directed against a tumor cell antigen and a cytotoxic trigger molecule and the bispecific antigen-binding polypeptide is linked to a linker, polymer, or biologically active molecule, wherein the method comprises contacting the bispecific antigen-binding polypeptide comprising the ribosomally incorporated non-naturally encoded amino acid, and allowing for an oxime bond to form between the non-naturally encoded amino acid and a linker, polymer, or biologically active molecule, wherein the non-naturally encoded amino acid has the structure;
1 Assignment
0 Petitions
Accused Products
Abstract
Novel antigen-binding polypeptides (ABP) and uses thereof are provided.
168 Citations
1 Claim
-
1. A method of making a bispecific antigen-binding polypeptide (ABP) comprising a sequence selected from SEQ ID NO:
- 19, 21, 23, 24, 26, 28, 30, 31, and comprising a ribosomally incorporated non-naturally encoded amino acid substitution, wherein the bispecific ABP is directed against a tumor cell antigen and a cytotoxic trigger molecule and the bispecific antigen-binding polypeptide is linked to a linker, polymer, or biologically active molecule, wherein the method comprises contacting the bispecific antigen-binding polypeptide comprising the ribosomally incorporated non-naturally encoded amino acid, and allowing for an oxime bond to form between the non-naturally encoded amino acid and a linker, polymer, or biologically active molecule, wherein the non-naturally encoded amino acid has the structure;
- 19, 21, 23, 24, 26, 28, 30, 31, and comprising a ribosomally incorporated non-naturally encoded amino acid substitution, wherein the bispecific ABP is directed against a tumor cell antigen and a cytotoxic trigger molecule and the bispecific antigen-binding polypeptide is linked to a linker, polymer, or biologically active molecule, wherein the method comprises contacting the bispecific antigen-binding polypeptide comprising the ribosomally incorporated non-naturally encoded amino acid, and allowing for an oxime bond to form between the non-naturally encoded amino acid and a linker, polymer, or biologically active molecule, wherein the non-naturally encoded amino acid has the structure;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeAmbrx, Inc. (Johnson & Johnson)
-
Original AssigneeAmbrx, Inc. (Johnson & Johnson)
-
InventorsCho, Ho Sung, Daniel, Thomas O., Wilson, Troy E., Cujec, Thomas P., Tian, Feng, Hays, Anna-Maria A., Kimmel, Bruce E., Ho, Lillian
-
Primary Examiner(s)DUFFY, BRADLEY
-
Application NumberUS11/873,372Publication NumberTime in Patent Office2,940 DaysField of Search435/69.2US Class Current1/1CPC Class CodesA61P 35/00 Antineoplastic agentsA61P 37/02 ImmunomodulatorsC07K 14/195 from bacteriaC07K 14/47 from mammalsC07K 16/2863 against receptors for growt...C07K 16/32 against translation product...C07K 2317/34 Identification of a linear ...C07K 2317/41 Glycosylation, sialylation,...C07K 2317/55 Fab or Fab'C07K 2317/622 Single chain antibody (scFv)
